INTRODUCTION
============

Kidney cancer, although not prevalent in the general population, has an annual incidence of 214,000 cases worldwide, with an estimated 143,000 deaths, making it the 16th leading cause of death \[[@B1]\].

The incidence of small renal tumors is increasing as a consequence of incidental findings secondary to the widespread use of imaging studies, which has allowed early diagnosis \[[@B2]\]. In the US, most renal masses are diagnosed at clinical stage cT1, with an average size of 3.5 cm \[[@B3]\]. The decision to treat at stage T1a (\<4 cm) allows a variety of options, such as surgery, ablation, or active surveillance, which should be the subject of discussion between the patient and his or her physician, with weighing of the risks and benefits \[[@B4]\].

At present, the clinical practice guidelines of the European Association of Urology (EAU), the American Urological Association (AUA), and the National Comprehensive Cancer Network (NCCN) recommend partial nephrectomy (PN), if it is anatomically possible, or radical nephrectomy for the treatment of small renal masses \[[@B5][@B6][@B7]\].

Multiple retrospective observational studies, clinical trials, and even meta-analyses show that PN preserves renal function. It has similar oncologic results and reduces the incidence of chronic kidney disease \[[@B4][@B8]\].

The preservation of renal function after PN is of great importance, mainly in patients with a single kidney or preexisting chronic kidney disease. However, PN per se is associated with a certain degree of deterioration in renal function, with an approximate 10% decrease in the global glomerular filtration rate (GFR) secondary to renal mass loss and irreversible ischemic damage due to clamping of the renal hilum during the procedure \[[@B9][@B10]\]. In contrast to this hypothesis, recent studies have shown that the kidney may be more tolerant to ischemia than previously thought and even that the majority of nephrons recover after ischemia during PN \[[@B11][@B12]\].

There are three types of clamping time of the renal hilum during PN: warm ischemia (clamping time \<30 minutes), cold ischemia (clamping time \>30 minutes), and no ischemia. Different studies have indicated that ischemia times \>30 minutes lead to deterioration in the GFR and subsequent renal atrophy \[[@B10][@B11]\]. The dissection of a renal tumor and subsequent nephrorrhaphy without clamping of the renal artery poses a challenging surgical field for a surgeon, but compared with warm ischemia, this technique may improve the preservation of renal function in well-selected patients \[[@B13][@B14][@B15]\].

It is necessary to determine whether PN without clamping of the renal hilum offers benefits not provided through PN with warm ischemia, because the former involves greater surgical complexity and higher intraoperative risks for patients owing to increased blood loss \[[@B2][@B13][@B15][@B16]\].

The objective of the present study was to determine the effectiveness and safety of PN without ischemia compared with PN with warm ischemia in patients with cT1 renal tumors in decreasing impaired renal function.

MATERIALS AND METHODS
=====================

We performed this study according to the Cochrane recommendations, and we registered the protocol in PROSPERO CRD42019121991

1. Inclusion criteria
---------------------

Clinical experiments (randomized controlled trials \[RCTs\]), quasi-experiments, and cohort studies were included (prospective and retrospective). Patients were older than 18 years who underwent PN with warm ischemia or without (Zero) ischemia for T1 renal tumors. Studies had to compare PN without ischemia with PN with warm ischemia.

2. Exclusion criteria
---------------------

Studies and patients with PN of lesions of nononcologic origin and studies for which data were unavailable were excluded.

3. Primary and secondary outcomes The primary outcome was impaired renal
------------------------------------------------------------------------

The primary outcome was impaired renal function, defined as the decrease in the postoperative GFR compared with that in the preoperative period. Secondary outcomes were 1) intraoperative bleeding, defined as the blood volume (in mL) lost during the procedure; 2) operative time, defined as the duration of the procedure; and 3) postoperative urine leakage, defined as the percentage of patients reporting postoperative urine leakage at the nephrorrhaphy site.

4. Search sources
-----------------

We performed a search strategy in the following databases from inception to the present: MEDLINE, EMBASE, LILACS, and the Cochrane Central Register of Controlled Trials (CENTRAL) ([Supplementary material](#S1){ref-type="supplementary-material"}).

We searched in other electronic sources to find additional studies such as Clinicaltrials.gov, DARE, PROSPERO, conference abstracts, Google Scholar, Open Grey database, thesis databases, and reference lists. When information was missing, we contacted the authors to expand our knowledge of published or unpublished reports. There were no language restrictions.

5. Extraction and analysis of data
----------------------------------

The two researchers identified and independently and blindly selected titles and abstracts obtained from electronic searches. The two evaluators analyzed their relevance by using a standardized eligibility format that included the predefined inclusion and exclusion criteria. We solved discrepancies for the inclusion of an article by consensus.

6. Extraction of information and management of data
---------------------------------------------------

The researchers extracted the data independently using a standard format. We obtained the following data: name of the first author, year of publication, country, year of study, type of study, sample size, outcome, and sociodemographic and clinical variables such as the number of patients per treatment arm, clinical stage, surgical technique, the measurement method of renal function, operative time, and postoperative urine leakage.

7. Evaluation of the risk of bias in the included studies
---------------------------------------------------------

We evaluated the quality of the studies on the basis of study methodology and reporting, according to the recommendations of the methodological index for nonrandomized studies (MINORS) tool. For clinical experiments, we used the Cochrane Risk of Bias tool.

8. Statistical analysis
-----------------------

We performed a statistical analysis in Review Manager ver. 5.4. We described the outcomes in terms of the difference in means (MD) with the corresponding confidence interval. We used a random-effects model according to the heterogeneity found in the studies. We reported the results in forest plots.

9. Sensitivity analysis
-----------------------

We performed a sensitivity analysis based on the type of study (RCT vs. nonrandomized) and the weighted studies.

RESULTS
=======

1. Selection of studies
-----------------------

With the search strategy, we found 5,682 articles. After eliminating duplicates, we included 14 articles ([Fig. 1](#F1){ref-type="fig"}).

2. Characteristics of the included studies
------------------------------------------

We included 13 observational studies, in which there was a description of functional and oncologic results in patients undergoing PN without ischemia compared with PN with warm ischemia \[[@B15][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B28]\], and one clinical trial \[[@B29]\] ([Table 1](#T1){ref-type="table"}) \[[@B15][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B28][@B29]\].

Eight of the included studies allowed evaluation of the primary outcome because data was provided on the change in estimated GFR (eGFR); in a smaller proportion of studies, the proposed secondary outcomes could be evaluated ([Table 2](#T2){ref-type="table"}) \[[@B15][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B28][@B29]\].

3. Evaluation of the risk of bias
---------------------------------

During the evaluation of the quality of the studies with the MINORS tool, we identified a high risk of bias in prospective data collection, the impartial assessment of the primary outcome, and calculation of the sample size. For the other items, the evaluation yielded mostly a low risk of bias ([Fig. 2A, B](#F2){ref-type="fig"}) \[[@B15][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B28]\]. For Andersen 2019, we found an unclear risk of bias for blinding since there was no clear description of this issue. We assessed the other items as having a low risk of bias ([Fig. 2C, D](#F2){ref-type="fig"}) \[[@B29]\].

4. Primary outcome: renal function
----------------------------------

We included seven studies in the meta-analysis, including 567 patients in the group without ischemia and 824 patients in the warm ischemia group. The analysis yielded a favorable outcome for techniques without ischemia compared with techniques with warm ischemia, with an MD of 3.50 mL/min/1.73 m^2^ (95% confidence interval \[CI\], 1.16 to 5.83; I^2^=56%) ([Fig. 3A](#F3){ref-type="fig"}) \[[@B18][@B19][@B22][@B23][@B26][@B27][@B29]\].

5. Secondary outcomes: intraoperative bleeding
----------------------------------------------

For the evaluation of intraoperative bleeding, we included 10 studies; the comparison between techniques without ischemia and those with warm ischemia did not identify statistically significant differences, with an MD of 55.46 mL (95% CI, −33.16 to 144.08; I^2^=97%) ([Fig. 3B](#F3){ref-type="fig"}) \[[@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B27][@B28][@B29]\].

6. Operative time
-----------------

Eight of the included studies comparatively evaluated the operative time between techniques with warm ischemia and without ischemia, which showed an MD of 1.87 minutes (95% CI, −20.47 to 24.21), with no statistically significant differences ([Fig. 3C](#F3){ref-type="fig"}) \[[@B17][@B19][@B20][@B23][@B26][@B27][@B28][@B29]\].

7. Urine leakage
----------------

When assessing postoperative urine leakage, we found that only 4 of the 13 studies included evaluated postoperative urine leakage. An odds ratio of 0.74 was found (95% CI, 0.12 to 4.62). No statistically significant differences were observed ([Fig. 3D](#F3){ref-type="fig"}) \[[@B15][@B18][@B21][@B27]\].

8. Sensitivity analysis
-----------------------

There were no changes in the results when we performed a sensitivity analysis based on the type of study (RCT vs. nonrandomized) and the weighted studies.

DISCUSSION
==========

1. Summary of the main findings
-------------------------------

We found a statistically significant difference in the decrease in deterioration of the eGFR, favoring techniques without ischemia. Nonetheless, this difference was not clinically meaningful. There were no statistically significant differences between intraoperative bleeding and operative time. In our evaluation of the proposed third secondary objective, postoperative leakage, we found no significant differences in the results for the two techniques described; however, only four studies assessed this outcome.

2. Contrast with the literature
-------------------------------

The impact of ischemia time in PN has been the subject of many debates, considering that the injury caused by the ischemia-reperfusion process is the leading cause of impaired renal function, independent of resected renal tissue, because it leads to hyperfiltration and secondary nephrosclerosis \[[@B10][@B11]\]. Given the above, the approach of PN without ischemia as the therapeutic option could minimize the deterioration in renal function in patients undergoing this intervention.

In a systematic review, Greco et al. \[[@B30]\] assessed functional and oncologic outcomes in patients who underwent PN. That study included all types of studies (e.g., case series), which permitted the inclusion of a higher number of studies. Besides, it did not have a risk of bias analysis, making unclear the quality of the included studies. The previous finding limits the generalization of the results in the population. Therefore, we decided to perform the current research by use of international recommendations for conducting systematic reviews to obtain the best evidence for treating our patients.

Our study results demonstrate the lowest impact on deterioration in the eGFR in patients undergoing PN without ischemia compared with those undergoing PN with warm ischemia, including studies with different surgical techniques (open, laparoscopic, and robot-assisted PN) \[[@B31][@B32]\]. However, this difference was not clinically significant. It is essential to mention that four of the included studies in which the change in eGFR was evaluated had a follow-up time of fewer than 6 months, which could be a confounding factor when assessing the real impact of GFR deterioration with different techniques.

The transfusion of red blood cells and all the risks that this involves (infectious and immunological) is one of the main concerns of current transfusion medicine, which explains the strict guidelines and the motivation to search for strategies to reduce intraoperative bleeding and with this the need for transfusion \[[@B33]\]. Liu et al. in 2014 \[[@B32]\] reported an increase in the need for transfusions in patients undergoing PN without ischemia. In our study, although the need for transfusion was not evaluated, we did not find statistically significant differences in intraoperative bleeding between the two groups. However, there was a tendency toward more significant bleeding associated with PN without ischemia. Also, there were no significant differences in postoperative urine leakage, which shows that the reported major complications for PN without ischemia do not differ from those for PN with warm ischemia.

Trehan in 2014 \[[@B31]\] showed no differences concerning the operative time when comparing the two PN techniques. We confirmed this finding in this study, and the evolution of laparoscopic and robotic procedures explains it.

There is a need for extensive prospective randomized studies with long-term follow-up that compare PN techniques with and without warm ischemia, with pre- and postoperative measurements of renal function with dimercaptosuccinic acid (DMSA), not with eGFR only. This idea would allow better discrimination of renal function and determination of the real impact of the technique used. We found one protocol published by Cindolo et al. in 2019 \[[@B34]\] (The CLOCK randomized phase III study); however, there have been no data until now.

3. Strengths and limitations
----------------------------

Our study, unlike the previously conducted studies, had a clear methodological strategy, and the quality of the included studies was evaluated to give our study greater scientific rigor. One of the limitations of our study was the short follow-up of the patients in the included studies. We found follow-ups of up to 1 postoperative week, which may mask the real impact of the different techniques used in PN. The retrospective observational characteristics of the studies and the lack of evaluation of adverse effects related to PN techniques, which did not allow us to estimate the impact of this item, are other limitations. The small sample size in most studies is another significant limitation. Besides, there was a high clinical and statistical heterogeneity that may prevent the generalization of these results.

CONCLUSIONS
===========

PN without ischemia showed reduced deterioration in the eGFR compared with that for PN with warm ischemia. There were no statistically significant differences in intraoperative blood loss and operative time between the two surgical techniques. Nonetheless, there were important limitations that may prevent the extrapolation of these results in clinical settings.
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###### Characteristics of the included studies

![](icu-61-464-i001)

  Author (year)                        No. of patients without ischemia/warm ischemia   Clinical stage   Surgical technique   Measurement method for renal function   Renal function outcome measure               Median follow-up (mo)
  ------------------------------------ ------------------------------------------------ ---------------- -------------------- --------------------------------------- -------------------------------------------- -----------------------
  Bhayani et al. \[[@B17]\] (2004)     42/48 patients                                   No information   LPN                  Serum creatinine                        Difference in mean Cr pre- and postsurgery   6 months
  Wang et al. \[[@B18]\] (2016)        22/22 patients                                   T1a              LPN                  eGFR                                    GFR changes                                  1 week postsurgery
  George et al. \[[@B19]\] (2013)      150/180 patients                                 T1a-T1b          LPN                  eGFR                                    GFR changes                                  6 months
  Koo et al. \[[@B20]\] (2010)         11/10 patients                                   T1a              LPN                  Serum creatinine                        Difference in mean Cr pre- and postsurgery   NA
  Kopp et al. \[[@B21]\] (2012)        64/164 patients                                  No information   LPN                  eGFR                                    GFR changes                                  \<12 months
  Lee et al. \[[@B22]\] (2014)         39/201 patients                                  T1a              OPN                  eGFR                                    GFR changes                                  12 months
  Tanagho et al. \[[@B23]\] (2012)     29/29 patients                                   T1a              RAPN                 eGFR                                    GFR changes                                  12 months
  Peyronnet et al. \[[@B24]\] (2017)   26/104 patients                                  T1a              RAPN                 eGFR                                    GFR changes                                  6 months
  Thompson et al. \[[@B15]\] (2010)    96/362 patients                                  T1a              LPN and OPN          eGFR                                    GFR changes                                  1 month
  Simone et al. \[[@B25]\] (2018)      485/221 patients                                 T1a-T1b          All                  eGFR                                    GFR changes                                  No information
  Salevitz et al. \[[@B26]\] (2015)    95/236 patients                                  No information   All                  eGFR                                    GFR changes                                  \<3 months
  Smith et al. \[[@B27]\] (2011)       192/116 patients                                 T1a              All                  eGFR                                    GFR changes                                  12 months
  Akca et al. \[[@B28]\] (2014)        35/206 patients                                  T1a              RAPN                 eGFR                                    GFR changes                                  12 to 24 months
  Anderson et al. \[[@B29]\] (2019)    40/40 patients                                   T1a              RAPN                 eGFR                                    GFR changes                                  3 months

LPN, laparoscopic partial nephrectomy; eGFR: estimated glomerular filtration rate; NA, not available; OPN, open partial nephrectomy; RAPN, robot-assisted partial nephrectomy.

###### Variables in the included studies

![](icu-61-464-i002)

  Study                                Technique          Operative time (min)   Estimated blood loss (mL)   eGFR, preoperative   eGFR, postoperative     Change in eGFR (−6 mo)   Postoperative urine leakage
  ------------------------------------ ------------------ ---------------------- --------------------------- -------------------- ----------------------- ------------------------ -----------------------------
  Bhayani et al. \[[@B17]\] (2004)     Without ischemia   190 (67--370)          390±457                     No information       No information          No information           No information
  Warm ischemia                        153 (75--280)      301±261                No information              No information       No information          No information           
  Wang et al. \[[@B18]\] (2016)        Without ischemia   No information         134±70                      86±19                84±21                   −1.5±4.7                 0.00%
  Warm ischemia                        No information     70±79                  90±21                       84±28                −6.4±3.8                0.00%                    
  George et al. \[[@B19]\] (2013)      Without ischemia   137 (35--441)          338 (50--1,700)             93.8 (28--292)       No information          −3.9 (−80.2--181.5)      No information
  Warm ischemia                        141 (31--400)      250.8 (5--1,300)       97 (32--384)                No information       −8.6 (−59.5 to 83.2)    No information           
  Koo et al. \[[@B20]\] (2010)         Warm ischemia      174±54.6               159±153                     No information       No information          No information           No information
  Without ischemia                     232±27             165±110                No information              No information       No information          No information           
  Kopp et al. \[[@B21]\] (2012)        Without ischemia   No information         200 (150--400)              No information       No information          No information           3.10%
  Warm ischemia                        No information     300 (200--440)         No information              No information       No information          7.30%                    
  Lee et al. \[[@B22]\] (2014)         Warm ischemia      No information         200 (40--1,700)             79.2 (34.6--125.1)   73.8 (35.5--111.4)      −7.9 (−57.1 to 24.1)     No information
  Without ischemia                     No information     200 (20--1,300)        80.7 (40.2--133.7)          63.7 (12.5--102.1)   −20.8 (−83.1 to 24.2)   No information           
  Tanagho et al. \[[@B23]\] (2012)     Without ischemia   127.0±37.9             146.4 (99.2)                84.8 (26.7)          79.9 (25.0)             −4.9 (8.9)               No information
  Warm ischemia                        123.8±33.7         103.9 (81.7)           85.8 (21.3)                 74.1 (21.1)          −11.7 (12.3)            No information           
  Peyronnet et al. \[[@B24]\] (2017)   Warm ischemia      No information         284.6                       78.4                 No information          −0.2                     No information
  Without ischemia                     No information     266.4                  84.9                        No information       −6.9                    No information           
  Thompson et al. \[[@B15]\] (2010)    Without ischemia   No information         No information              54 (16--95)          No information          No information           1.00%
  Warm ischemia                        No information     No information         61 (11--133)                No information       No information          5.00%                    
  Simone et al. \[[@B25]\] (2018)      Warm ischemia      No information         No information              86.4±17.7            78.5                    No information           No information
  Without ischemia                     No information     No information         86.4±15.4                   79.2                 No information          No information           
  Salevitz et al. \[[@B26]\] (2015)    Without ischemia   143±65                 No information              73.1±22.3            67.1±23.8               −6±15.5                  No information
  Warm ischemia                        172±49             No information         80.0±20.0                   72.9±21.3            −6.07±13.5              No information           
  Smith et al. \[[@B27]\] (2011)       Warm ischemia      226.5 (181--265)       500 (250--1,000)            72.2 (57.1--86.9)    66.3 (52.9--78.3)       −9.8 (−19--0)            4.70%
  Without ischemia                     192 (144--262)     200 (100--700)         77.5 (61--88.8)             68.9 (55.7--78.5)    −12.3 (−20.9--0.3)      0.80%                    
  Akca et al. \[[@B28]\] (2014)        Without ischemia   180±63.3               210 (100--400)              78.3±26.3            75.5±25.1               No information           No information
  Warm ischemia                        180±54             150 (100--250)         85.1±22.4                   75±22.6              No information          No information           
  Anderson et al. \[[@B29]\] (2019)    Warm ischemia      178±44.4               184.1±193.3                 85.8 ±21             76 ±23.3                −10.7±17.5               No information
  Without ischemia                     156±40.6           178.5±207.5            92±21.6                     81.8±19.3            −9.4±14.8               No information           

Values are presented as mean (range) or number only or mean±standard deviation.

eGFR, estimated glomerular filtration rate.
